Prosecution Insights
Last updated: April 19, 2026
Application No. 18/032,933

PROCESS FOR THE PURIFICATION OF AN ACIDIC HUMAN MILK OLIGOSACCHARIDE FROM FERMENTATION BROTH

Non-Final OA §112
Filed
Apr 20, 2023
Examiner
ORME, PATRICK JAMES
Art Unit
1779
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Frieslandcampina Nederland B V
OA Round
1 (Non-Final)
59%
Grant Probability
Moderate
1-2
OA Rounds
3y 8m
To Grant
74%
With Interview

Examiner Intelligence

Grants 59% of resolved cases
59%
Career Allow Rate
280 granted / 474 resolved
-5.9% vs TC avg
Moderate +15% lift
Without
With
+15.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 8m
Avg Prosecution
20 currently pending
Career history
494
Total Applications
across all art units

Statute-Specific Performance

§101
0.9%
-39.1% vs TC avg
§103
38.5%
-1.5% vs TC avg
§102
17.0%
-23.0% vs TC avg
§112
35.7%
-4.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 474 resolved cases

Office Action

§112
DETAILED ACTION This detailed action is in response to the application filed on April 20, 2023, and any subsequent filings. Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Objections Claims 1-15 are objected to because of the following informalities: In Claim 1, the claim should begin with “A” to render the claim grammatically correct; In Claim 1, the positive sign should be used for H+ to align with conventional terminology; In Claim 1, the negative sign should be sued for Cl- to align with conventional terminology; Claims 2-14 should each begin with “The” to render the claims grammatically correct; In Claim 9, the first instance of “MF” should be proceeded by the full name of the shorthand for microfiltration; and, In Claim 15, the claim should begin with “A” to render the claim grammatically correct. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. Claims 1-15 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. In step (i) of Claim 1, the use of “a” instead of “the” makes the language unclear if it referring to the same fermentation broth recited in the preamble. For purposes of examination, the fermentation broth in both the preamble and step (i) are considered to be the same. In Claims 6 and 10, the recitation to step (vi) of Claim 1 renders the claim unclear because step (vi) is optional and may not be present. The dependent claims not specifically detailed above contain the limitations of the recited claims and thus are rejected for the same reasons. Allowable Subject Matter The following is a statement of reasons for the indication of allowable subject matter: Claim 1 distinguishes over the combination of the closest prior art, Helfrich, et al., International Publication No. WO 2019/101629 A1 (“Helfrich”) and Jennewein, et al., International Publication No. WO 2019/043029 A1 (“Jennewein”). Helfrich teaches the claimed process (Figs. 1-4) using a weakly basic anion exchange material (Pg22/L33-34) in Cl- form (Pg21/L29-34,Pg23/L10-12) except the adsorption step and pH ranges. Further, unlike the claimed invention, Helfrich requires a need for neutralization step after subjecting the solution to a cation exchange material but prior to the anion exchange (Pg19/L18-21, Pg20/L1-2, Pg20/L35-Pg21/L3, Pg21/L14-20,30-34). Jennewein discloses the adsorption step (Pg27/L29-Pg28/L2) but also requires neutralization (Pg27/L10-11) prior to using a strong basic anion exchange material in Cl- form (Pg27/L11-13). Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to PATRICK ORME whose telephone number is (408)918-7585. The examiner can normally be reached Monday - Thursday, 7:30 am - 6:00 pm Pacific Time. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Bobby Ramdhanie can be reached at (571) 270-3240. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /PATRICK ORME/Primary Examiner, Art Unit 1779
Read full office action

Prosecution Timeline

Apr 20, 2023
Application Filed
Jan 23, 2026
Non-Final Rejection — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599852
FILTRATION DEVICE
2y 5m to grant Granted Apr 14, 2026
Patent 12594526
FORWARD OSMOSIS FILTRATION CELL, AND METHODS OF FILTERING WATER WITH A FORWARD OSMOSIS FILTRATION CELL
2y 5m to grant Granted Apr 07, 2026
Patent 12582943
SYSTEM AND METHOD FOR GROUNDWATER TREATMENT FOR NON-POTABLE USE
2y 5m to grant Granted Mar 24, 2026
Patent 12577131
TRANSMEMBRANE PRESSURE DIFFERENCE INFERENCE DEVICE AND DIFFUSED AIR AMOUNT CONTROL DEVICE
2y 5m to grant Granted Mar 17, 2026
Patent 12569609
TEMPERATURE MANAGEMENT SYSTEM FOR PATIENTS DURING STATIONARY AND MOBILE ECLS/ECMO THERAPY
2y 5m to grant Granted Mar 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
59%
Grant Probability
74%
With Interview (+15.0%)
3y 8m
Median Time to Grant
Low
PTA Risk
Based on 474 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month